Literature DB >> 20194529

Involvement of multidrug resistance-associated protein 4 in efflux transport of prostaglandin E(2) across mouse blood-brain barrier and its inhibition by intravenous administration of cephalosporins.

Shin-ichi Akanuma1, Ken-ichi Hosoya, Shingo Ito, Masanori Tachikawa, Tetsuya Terasaki, Sumio Ohtsuki.   

Abstract

Prostaglandin E(2) (PGE(2)) acts as a modulator of synaptic signaling and excitability in the brain. Because PGE(2) is barely inactivated enzymatically in adult brain, its brain level is considered to be controlled by efflux transport across the blood-brain barrier (BBB). The purpose of the present study was to clarify the efflux transport of PGE(2) at the BBB and the interaction of various drugs with this process. [(3)H]PGE(2) was eliminated from brain across the BBB with a half-life of 16.3 min, and the elimination was inhibited by 3 mM unlabeled PGE(2). Multidrug resistance-associated protein 4 (MRP4/ABCC4) was reported to be localized at the luminal membrane of the BBB. MRP4-expressing membrane vesicles showed significant uptake of [(3)H]PGE(2) and the uptake was inhibited by cefmetazole with an IC(50) value of 10.2 microM. At the concentration of 20 microM, several drugs, including cefazolin, cefotaxime, ceftriaxone, and ketoprofen, significantly inhibited [(3)H]PGE(2) uptake into MRP4-expressing membrane vesicles. Using the brain efflux index method, preadministration of cefmetazole, cefazolin, ceftriaxone, and cefotaxime was found to inhibit [(3)H]PGE(2) efflux from brain across the BBB. Furthermore, intravenous administration of the cefmetazole dose dependently reduced [(3)H]PGE(2) elimination across the BBB (ID(50) = 120 mg/kg). These results indicate that PGE(2) is eliminated from the brain by MRP4-mediated efflux transport at the BBB, and peripheral administration of cefmetazole decreases the efflux transport of PGE(2) at the BBB; this interaction may influence brain function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194529     DOI: 10.1124/jpet.109.165332

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells.

Authors:  Michelle A Erickson; Yoichi Morofuji; Joshua B Owen; William A Banks
Journal:  J Pharmacol Exp Ther       Date:  2014-04-04       Impact factor: 4.030

2.  Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes.

Authors:  Yassine Sassi; Aniella Abi-Gerges; Jeremy Fauconnier; Nathalie Mougenot; Steven Reiken; Kobra Haghighi; Evangelia G Kranias; Andrew R Marks; Alain Lacampagne; Stefan Engelhardt; Stephane N Hatem; Anne-Marie Lompre; Jean-Sébastien Hulot
Journal:  FASEB J       Date:  2011-11-16       Impact factor: 5.191

Review 3.  Pharmacogenetics of chronic pain and its treatment.

Authors:  Svatopluk Světlík; Karolína Hronová; Hana Bakhouche; Olga Matoušková; Ondřej Slanař
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

4.  Purinergic signaling induces cyclooxygenase-1-dependent prostanoid synthesis in microglia: roles in the outcome of excitotoxic brain injury.

Authors:  Josef Anrather; Eduardo F Gallo; Takayuki Kawano; Marcello Orio; Takato Abe; Camile Gooden; Ping Zhou; Costantino Iadecola
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

5.  Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole.

Authors:  Shin-Ichi Akanuma; Yasuo Uchida; Sumio Ohtsuki; Masanori Tachikawa; Tetsuya Terasaki; Ken-Ichi Hosoya
Journal:  Fluids Barriers CNS       Date:  2011-10-21

6.  Cellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid.

Authors:  Nathaniel W Snyder; Sonia D Revello; Xiaojing Liu; Suhong Zhang; Ian A Blair
Journal:  J Lipid Res       Date:  2013-08-14       Impact factor: 5.922

7.  P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac.

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Yifeng Zhang; Mei-Li Laracuente; Kristin M DeMarco; Patrick T Ronaldson; Thomas P Davis
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.